HLB Co.,LTD.

028300KOSDAQPharmaceuticals

HLB Co.,LTD. (028300, KOSDAQ) reported KRW 84bn revenue in 2025.

Reported financials

Figures are as filed with the Korean regulator, in billions of won (KRW bn). We do not convert to dollars — an exchange rate would be a number we made up, not one the company reported.

YearRevenueOperating profitNet profitAssetsEquityBasis
202343-125-206752582Consolidated
202468-119-108887652Consolidated
202584-104-235930494Consolidated

Ratios, year by year

Each ratio is computed inside its own year. A dash means the input was missing or the denominator was zero — not that the value is zero.

YearOperating marginNet marginEquity / assetsReturn on equity
2023-291.4%-480.3%77.5%-35.4%
2024-174%-158.6%73.5%-16.6%
2025-123.8%-279.7%53.2%-47.6%

Revenue moved 96.2% between 2023 and 2025.

These are arithmetic, not judgements. We do not say whether a margin is good or bad, and we do not rank companies against each other.

Market size

Market capitalisationKRW 4,196bn
Close priceKRW 31,500
Listed shares133,198,223
Price as of20260909

Market capitalisation is what buyers are betting the company is worth. It is not something the company produced, so we never present it as output or productivity.

Workforce — a side measure, not the main one

Employees (2025)151
Women94 (62.3%)
Average tenure4.7 years
Annual pay, menKRW 88,616,000
Annual pay, womenKRW 43,590,766
Pay ratio, women to men49.2%

Other companies in Pharmaceuticals

181 listed companies file under this classification. Showing 12.

See the whole Pharmaceuticals list →